ArticleslgStudy

chemistry

Vidofludimus

Vidofludimus is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Vidofludimus rather than just read about it. In short: Vidofludimus is an orally administered small-molecule compound and an investigational new drug. Its calcium salt is being evaluated to treat multiple sclerosis (MS), ulcerative colitis and other chronic inflammatory and autoimmune diseases.

Vidofludimus — main illustration
Vidofludimus — illustration

Key takeaways

  • Vidofludimus belongs to chemistry; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Vidofludimus to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Vidofludimus from memory before moving on to harder problems.

Reference excerpt

Vidofludimus is an orally administered small-molecule compound and an investigational new drug. Its calcium salt is being evaluated to treat multiple sclerosis (MS), ulcerative colitis and other chronic inflammatory and autoimmune diseases. It is a nuclear receptor-related 1 (Nurr1) activator and dihydroorotate dehydrogenase (DHODH) inhibitor. Vidofludimus is being developed by the American-German biotechnology company Immunic Therapeutics.

Potential medical applications As of 2025, vidofludimus calcium is not approved in any country and is being tested in clinical trials for the treatment of MS, including the Phase 3 ENSURE studies in relapsing multiple sclerosis (RMS), as well as for the treatment of post‑COVID syndrome (PCS). In addition, the investigational drug was tested in Phase 2 studies in relapsing‑remitting MS (RRMS), progressive MS (PMS), moderate to severe ulcerative colitis (UC), primary sclerosing cholangitis (PSC) and COVID-19, as well as in Phase 1 studies in healthy volunteers. As studies have shown, the safety profile observed is similar to that of placebo. The pharmacokinetic profile, with a terminal plasma half-life of approximately 30 hours, enables once-daily oral administration.

Mechanism of action Vidofludimus calcium acts as an activator of nuclear receptor-related 1 (Nurr1), a neuroprotective transcription factor and emerging target for neurodegenerative diseases. Activation of Nurr1 is associated with neuroprotective effects by acting on microglia, astrocytes, and neurons. In microglia and astrocytes, Nurr1 activation leads to a reduction in pro-inflammatory cytokines and blocks the production of direct neurotoxic agents such as reactive oxygen species and nitric oxide. Increased Nurr1 activity in neurons promotes neuronal survival and differentiation, as well as improved neurotransmission. Therefore, activation of Nurr1 by vidofludimus calcium could reduce or halt neurodegeneration and the progression of disability in patients suffering from MS and other degenerative diseases. In addition to its effects as a Nurr1 activator, vidofludimus calcium is also an inhibitor of dihydroorotate dehydrogenase (DHODH), a mitochondrial key enzyme required for pyrimidine de novo biosynthesis. In contrast to resting lymphocytes, active and rapidly proliferating lymphocytes rely on this enzyme to meet their demand for pyrimidines. To counteract an activated and pathogenic lymphocyte population, DHODH blockade is of clinical interest: the activated lymphocytes undergo metabolic stress, which subsequently induces apoptosis of the activated immune cells.

Pharmaceutical formulation Vidofludimus calcium is formulated as an oral tablet. Current dose strengths used in clinical studies are 30 mg and 45 mg.

Medical history The company behind vidofludimus calcium, Immunic Therapeutics, was founded in 2016 in Planegg-Martinsried, Germany. In September 2016, Immunic Therapeutics received a Series A funding of €17.5 million. With this money, Immunic Therapeutics acquired immunology programs from company 4SC. In March 2021, the outstanding royalties with 4SC were settled, resulting in vidofludimus calcium being fully owned by Immunic.

References

Illustrations

Vidofludimus illustration

Worked examples

Example 1 — a first encounter with Vidofludimus

Start with the simplest possible case. Write down what Vidofludimus claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Vidofludimus before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Vidofludimus ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Vidofludimus

In research
Vidofludimus appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Vidofludimus in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Vidofludimus is common in secondary-school and first-year university syllabi. It links to neighbouring topics 3-Methoxyphenyl compounds, Anti-inflammatory agents, Biphenyls, so understanding it makes those chapters shorter.
In everyday life
Look for Vidofludimus outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Vidofludimus” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Vidofludimus in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Vidofludimus means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Vidofludimus out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Vidofludimus in simple terms?

Vidofludimus is an orally administered small-molecule compound and an investigational new drug. Its calcium salt is being evaluated to treat multiple sclerosis (MS), ulcerative colitis and other chronic inflammatory and autoimmune diseases.

Why does Vidofludimus matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Vidofludimus?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Vidofludimus.

Tags

  • 3-Methoxyphenyl compounds
  • Anti-inflammatory agents
  • Biphenyls
  • Carboxamides
  • Carboxylic acids
  • Cyclopentanes
  • Fluorobenzene derivatives

Keep exploring